AC-262 (AC-262,536, sold as accadrine) is a nonsteroidal SARM that Acadia Pharmaceuticals described in 2008. In a 2-week study in castrated rats it grew the levator ani muscle and lowered LH, with only weak effects on the prostate (Piu 2008). That rat study is the only published data on its effects: it has never been tested in people, and we found no published human case report naming it (ClinicalTrials.gov). It is not approved anywhere, and anti-doping agencies treat it as a banned SARM (UK Anti-Doping).

Below: what AC-262 is and does, the claims that are not supported, its possible side effects, dosage and half-life, legal status, and links to our longer AC-262 guide and the related ACP-105.

What is AC-262 (AC-262536)?

AC-262536 is a selective androgen receptor modulator from Acadia Pharmaceuticals in San Diego. It is also written AC-262,536, AC262536 or AC262, and UK Anti-Doping lists accadrine as a name it is sold under (PubChem CID 44512434; UK Anti-Doping). In lab tests it was a potent and selective androgen-receptor ligand that only partly activates the receptor compared with testosterone (a partial agonist) (Piu 2008).

Chemical structure of AC-262536 (accadrine), a nonsteroidal SARM
AC-262536 is a nonsteroidal partial agonist of the androgen receptor.

We found no record of clinical development after the 2008 rat paper. Later publications are detection studies for doping control and horse racing (Cutler 2021; Stacchini 2021).

What does AC-262 do? The evidence

Study Model What it found Evidence
Piu 2008 Cells; castrated male rats, 2 weeks Partial agonist compared with testosterone. Improved anabolic measures, especially growth of the levator ani muscle. Suppressed the raised LH of castrated rats. Only weak effects on prostate and seminal vesicle weights. Cell, animal
Cutler 2021 Two Thoroughbred horses The drug and its breakdown products were found in urine, blood and hair. Animal (detection)
Stacchini 2021; Gheddar 2021 (Stacchini 2021; Gheddar 2021) Human urine and hair samples Validated test methods detect AC-262536. Lab methods

The abstract of the rat study gives no numbers, so we do not quote any. No study has measured muscle, strength, fat or any other outcome in people (ClinicalTrials.gov). Compare it in the SARMs database.

Benefits claimed online vs the evidence

  • Muscle and strength: one 2-week study in castrated rats showed anabolic effects (Piu 2008). Not tested in people.
  • “Raises testosterone”: not supported. In castrated rats it lowered LH, the hormone that drives testosterone production, which points to suppression, not a boost (Piu 2008).
  • Alzheimer’s disease: the mouse memory studies often quoted here were done with ACP-105, a different Acadia SARM, combined with another drug (George 2013); none was done with AC-262.
  • Prostate: weak effects on prostate weight in rats (Piu 2008). There is no evidence that it lowers prostate cancer risk.
  • “66% anabolic, 27% androgenic”: figures like these circulate online; we could not trace them to a published source.

AC-262 results and before-and-after reports

There are no measured human results. Our long-form AC-262 guide covers what users report, with the evidence alongside.

AC-262 side effects

Unknown in people, because it has never been studied in humans and we found no case report naming it (ClinicalTrials.gov). What is known:

  • Lower LH (rats): it suppressed raised LH in castrated rats, a sign that it acts on the pituitary like an androgen (Piu 2008).
  • Harms linked to SARM products: the FDA says life-threatening reactions, including liver injuries needing hospital care, have occurred in people taking SARM products, and lists possible risks including heart attack or stroke, liver failure and infertility (FDA).
  • Mislabeled products: in a test of 44 products sold online as SARMs, only 52% contained a SARM and 41% matched the label (Van Wagoner 2017).

Across SARMs: SARMs side effects, liver and hair loss.

Does AC-262 suppress testosterone? PCT

In castrated rats it lowered LH (Piu 2008). How much it would lower testosterone in people is unknown, because it has never been measured. What is known about recovery after SARMs and the PCT drugs that have been studied: PCT after SARMs and the PCT and bloodwork planner. Tests worth knowing about: SARMs bloodwork guide.

Testosterone suppression: AC-262 compared Sarmguide score from 0 (none found) to 3 (marked suppression), based on the cited studies of each compound. "(animal)" means the score rests on animal data because suppression was not measured in men; compounds with no data at all are left out. AC-262: Shown in rats; not measured in people. In castrated rats, AC-262536 suppressed elevated LH, the pituitary hormone that drives testosterone production. How much it would lower testosterone in people is unknown.
Testosterone suppression: AC-262 comparedLGD-4033: Marked; AC-262: Moderate (animal); Andarine (S4): Moderate (animal); Ostarine: Moderate; RAD-140: Moderate (animal); S-23: Moderate (animal); MK-677: Mild; Anastrozole: None found; Clomiphene: None found; Enclomiphene: None foundNone foundMildModerateMarkedLGD-4033LGD-4033: MarkedMarkedAC-262AC-262: Moderate (animal)Moderate (anim…Andarine (S4)Andarine (S4): Moderate (animal)Moderate (anim…OstarineOstarine: ModerateModerateRAD-140RAD-140: Moderate (animal)Moderate (anim…S-23S-23: Moderate (animal)Moderate (anim…MK-677MK-677: MildMildAnastrozoleAnastrozole: None foundNone foundClomipheneClomiphene: None foundNone foundEnclomipheneEnclomiphene: None foundNone found

Source: Sarmguide compound database; AC-262: Pharmacological characterization of AC-262536, a novel selective androgen receptor modulator (2008).

Embed this chart

Free to use with the credit link.

AC-262 dosage, cycle length and half-life

No human dose or cycle length has been studied. The only efficacy study used castrated rats for 2 weeks, and rat doses do not translate to people (Piu 2008). No half-life has been published in people or animals. Products are sold by label strength; SwissChems, for example, sells AC-262 (accadrine) as 10 mg capsules. Our AC-262 guide covers what users report about dosing and timing.

  • United States: not FDA-approved. AC-262 is not named in the FDA notices we found, but the FDA says products sold as SARMs are unapproved drugs, not dietary supplements (FDA).
  • United Kingdom: UK Anti-Doping lists accadrine (AC-262,536) among commonly available SARMs, says no SARM is approved for human use, and notes that SARMs are illegal to sell or advertise as food or in supplements (UK Anti-Doping).
  • Australia: not named, but SARMs as a class are prescription-only and possession without authority is illegal (Poisons Standard 2026).

More: are SARMs legal?

AC-262 in sport and drug tests

It is not named on WADA’s 2026 List, but S1.2 bans SARMs as a class (“including, but not limited to” the examples) (WADA 2026), and UK Anti-Doping lists accadrine as prohibited (UK Anti-Doping). Validated anti-doping methods detect it in human urine and hair (Stacchini 2021; Gheddar 2021). We found no human excretion study, so detection times in people are unknown. See SARMs drug test.

AC-262 vs ACP-105 and ostarine

Compound Developer Evidence
AC-262 Acadia Pharmaceuticals (2008) One 2-week study in castrated rats (Piu 2008)
ACP-105 Acadia Pharmaceuticals (2009) A 2-week castrated rat study plus mouse studies of anxiety and memory (Schlienger 2009; George 2013)
Ostarine GTx; now Veru Phase 2 and Phase 3 human trials; +1.3 kg lean mass vs placebo at 3 mg/day (Dalton 2011)

AC-262 and ACP-105 are both nonsteroidal partial agonists from the same company, and neither has been tested in people. Compare them with the compare tool.

Buying AC-262: what to check

With no human data and frequent mislabeling across SARM products (Van Wagoner 2017), the certificate of analysis is the only check on what is in the bottle. Learn how to read a lab test. Our current pick is SwissChems, which publishes lot-specific lab reports; see our SwissChems review and where to buy SARMs.

Bottom line

AC-262 is a partial-agonist SARM with one 2-week rat study behind it: it grew a rat muscle, lowered LH and had weak effects on the prostate. It has never been given to people in a study, its half-life is unknown, and claims about raising testosterone or helping with Alzheimer’s are not supported. It is banned in sport and cannot legally be sold as a supplement in the US or UK.

Charts

Half-life of AC-262 compared Elimination half-life in people, where measured (log scale; bars show the reported range). Values from different studies and routes are not directly comparable.
Half-life of AC-262 comparedIpamorelin: ~2 h; Enclomiphene: ~8–10 h; Ostarine: ~14–24 h; Clomiphene: ~5–24 h (No single value: enclomiphene part ~5–10 h; zuclomiphene part ~24 h with a very long tail (detectable for over a month)); LGD-4033: ~24–36 h (24–36 h); RAD-140: ~45 h; Anastrozole: ~2–2.1 days (~50 h); Tamoxifen: ~5–7 days (~5–7 days (tamoxifen); ~14 days (N-desmethyltamoxifen, main active metabolite)); CJC-1295: ~5.8–8.1 days (~6–8 days); AC-262: not established1 h3 h6 h12 h1 day3 days1 weekIpamorelinIpamorelin: ~2 h~2 hEnclomipheneEnclomiphene: ~8–10 h~8–10 hOstarineOstarine: ~14–24 h~14–24 hClomipheneClomiphene: ~5–24 h (No single value: enclomiphene part ~5–10 h; zuclomiphene part ~24 h with a very long tail (detectable for over a month))~5–24 hLGD-4033LGD-4033: ~24–36 h (24–36 h)~24–36 hRAD-140RAD-140: ~45 h~45 hAnastrozoleAnastrozole: ~2–2.1 days (~50 h)~2–2.1 daysTamoxifenTamoxifen: ~5–7 days (~5–7 days (tamoxifen); ~14 days (N-desmethyltamoxifen, main active metabolite))~5–7 daysCJC-1295CJC-1295: ~5.8–8.1 days (~6–8 days)~5.8–8.1 daysAC-262not established

Source: Sarmguide compound database; AC-262 value: Pharmacological characterization of AC-262536, a novel selective androgen receptor modulator (2008).

Embed this chart

Free to use with the credit link.

More on AC-262

Frequently asked questions

What is AC-262 (accadrine)?

An untested partial-agonist SARMEvidence: Animal

AC-262 (AC-262,536, sold as accadrine) is a nonsteroidal SARM described by Acadia Pharmaceuticals in 2008. It has only been tested in rats.

Read the full section

What does AC-262 do?

Unknown in peopleEvidence: Animal

In one 2-week study in castrated rats it grew the levator ani muscle and lowered LH, with weak effects on the prostate. Nothing has been measured in people.

Read the full section

What are the benefits of AC-262?

None shown in peopleEvidence: Animal

Only rat data exist: anabolic effects, especially on the levator ani muscle, over 2 weeks. No benefit has been measured in people.

Read the full section

Does AC-262 increase testosterone?

No evidence it doesEvidence: Animal

In castrated rats it lowered LH, the hormone that drives testosterone production, which points to suppression rather than a boost.

Read the full section

Has AC-262 been tested in humans?

NoEvidence: Limited

ClinicalTrials.gov lists no trials, and no published human study or case report naming it has been found.

What are the side effects of AC-262?

Unknown in peopleEvidence: Limited

It has never been studied in humans. The FDA warns that SARM products have caused liver injuries needing hospital care and lists heart attack or stroke among possible risks.

Read the full section

Does AC-262 need PCT?

UnknownEvidence: Animal

Its effect on testosterone in people has never been measured. In castrated rats it lowered LH.

Read the full section

What is the half-life of AC-262?

UnknownEvidence: Limited

No half-life has been published in people or animals.

Read the full section

What dose of AC-262 has been studied?

No human dose studiedEvidence: Animal

The only efficacy study used castrated rats for 2 weeks, and rat doses do not translate to people.

Read the full section

AC-262 vs ACP-105: what is the difference?

Sister SARMs, both untestedEvidence: Animal

Both are nonsteroidal partial-agonist SARMs from Acadia Pharmaceuticals, published in 2008 and 2009. Neither has been tested in people; ACP-105 also has mouse studies.

Read the full section

Is AC-262 legal, and is it banned in sport?

Not approved; banned in sportEvidence: Law

It is not approved anywhere and cannot legally be sold as a supplement in the US or UK. WADA bans SARMs as a class under S1.2, and UK Anti-Doping lists accadrine as prohibited.

Read the full section

Can AC-262 be detected in a drug test?

YesEvidence: Lab

Validated anti-doping methods detect AC-262536 in human urine and hair. Detection times in people are unknown.

Read the full section

Sources

  1. Pharmacological characterization of AC-262536, a novel selective androgen receptor modulator 2008 · PMID 18164613
  2. ClinicalTrials.gov search for 'AC-262536', 'AC-262,536' and 'accadrine': no studies found (checked 30 October 2026) 2026
  3. SARMs | UK Anti-Doping (supplement ingredient warning, updated 29 April 2026) 2026
  4. PubChem: AC-262536 (CID 44512434), names and synonyms 2026
  5. Equine metabolism of the selective androgen receptor modulator AC-262536 in vitro and in urine, plasma and hair following oral administration 2021 · PMID 32959959
  6. Simultaneous detection of different chemical classes of selective androgen receptor modulators in urine by liquid chromatography-mass spectrometry-based techniques 2021 · PMID 33383501
  7. Development and validation of SARMs and metabolic modulators screening in hair using UHPLC-MS/MS: Application to a doping case and first identification of S23 in authentic human hair 2021 · PMID 34814052
  8. Nonsteroidal selective androgen receptor modulators and selective estrogen receptor β agonists moderate cognitive deficits and amyloid-β levels in a mouse model of Alzheimer's disease 2013 · PMID 24020966
  9. FDA: Certain bodybuilding products put consumers at risk for heart attack, stroke, serious liver damage and more (content current as of 2 December 2025) 2025
  10. Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet 2017 · PMID 29183075
  11. Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026 (F2026L00633) 2026
  12. WADA: The Prohibited List (2026 List, in force from 1 January 2026) 2026
  13. Synthesis, structure-activity relationships, and characterization of novel nonsteroidal and selective androgen receptor modulators 2009 · PMID 19856921
  14. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial 2011 · PMID 22031847